CenterBook Partners LP Reduces Stake in Johnson & Johnson $JNJ

CenterBook Partners LP lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 87.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,126 shares of the company’s stock after selling 71,021 shares during the period. CenterBook Partners LP’s holdings in Johnson & Johnson were worth $1,878,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Abich Financial Wealth Management LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $26,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth about $28,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Semmax Financial Advisors Inc. lifted its stake in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after buying an additional 72 shares in the last quarter. Finally, Compass Financial Services Inc boosted its holdings in Johnson & Johnson by 707.1% in the 3rd quarter. Compass Financial Services Inc now owns 226 shares of the company’s stock worth $42,000 after buying an additional 198 shares during the period. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on JNJ. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. TD Cowen upped their price target on Johnson & Johnson from $222.00 to $250.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings restated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. Citigroup boosted their price objective on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Argus raised their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $233.73.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $246.90 on Friday. The firm has a market capitalization of $595.00 billion, a PE ratio of 22.34, a price-to-earnings-growth ratio of 2.38 and a beta of 0.35. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $246.96. The business’s 50-day moving average price is $220.45 and its 200-day moving average price is $198.55.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong clinical data: Phase 1b/2 OrigAMI‑4 showed a 56% overall response rate (10% complete responses) for subcutaneous amivantamab (RYBREVANT FASPRO) plus immunotherapy in first‑line recurrent/metastatic head & neck cancer — data that can materially broaden commercial and label potential if confirmed. Read More.
• Positive Sentiment: Regulatory acceleration: FDA granted Breakthrough Therapy Designation for subcutaneous amivantamab in advanced head & neck cancer — could shorten development timelines and improve commercial outlook. Read More.
• Positive Sentiment: Factory investment: J&J announced >$1 billion to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania — supports scaling of cell/biologics supply and signals continued capex to back pipeline commercialization. Read More.
• Positive Sentiment: Shareholder returns & analyst momentum: JNJ raised its quarterly payout (supports dividend investor base) and analysts have been raising targets/ratings, underpinning bullish sentiment. Read More.
• Neutral Sentiment: Strategic sale being explored: Bloomberg/Reuters report J&J is preparing a potential sale (~$20B) of its orthopedics unit; could unlock value but is early and dependent on deal terms/market appetite. Read More.
• Neutral Sentiment: Options & market attention: Elevated options activity and analyst write‑ups are amplifying near‑term moves but don’t change fundamentals. Monitor for concentrated directional trades. Read More.
• Negative Sentiment: Insider selling: Two executive vice presidents disclosed sizable share sales (combined filings) last week — a near‑term negative signal for some investors, though not proof of change in fundamentals. Read More.
• Negative Sentiment: Legal overhang: Coverage highlighting rising talc litigation risk continues to weigh on valuation and can cap multiple expansion despite operational gains. Read More.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.